Business
Entera Bio Ltd. Announces Highly Encouraging Oral PTH Market Survey Results
‒ Approximately 85% of Clinicians Surveyed Likely to Prescribe Oral Parathyroid Hormone (PTH) to Treat Moderate to Severe Osteoporosis ‒ ‒ Oral PTH Described
About this update from Entera Bio Ltd.
[{"type":"text","content":"‒ Approximately 85% of Clinicians Surveyed Likely to Prescribe Oral Parathyroid Hormone (PTH) to Treat Moderate to Severe Osteoporosis ‒\n ‒ Oral PTH Described by Clinicians as Potential Game-Changer that Addresses Substantial Unmet Need with Possibility of Improving Patient Compliance and Comfort ‒ ‒ Potential to Significantly Expand the Multi-Billion Dollar Global Market; More than Half of Clinicians Likely to Increase Usage of PTH to Treat Osteoporosis if an Effective Orally Delivered Product is Available ‒ BOSTON and JERUSALEM, July 22, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced today the results from two primary market research studies of clinicians who treat osteoporosis patients. The studies were conducted by a third-party firm with a goal of gaining a better understanding of the perceived value and potential market penetration of an orally-delivered parathyroid hormone product in the treatment of osteoporosis. The survey populations were comprised of clinicians who frequently prescribe osteoporosis products including endocrinologists, gynecologists, orthopedists, and general practitioners, with over 70% of their osteoporosis patients having moderate to severe osteoporosis. One study surveyed clinicians in the U.S., Canada, and Europe, and the second surveyed clinicians in Japan. In the two studies, physicians were presented with a description of an oral PTH product that provides similar efficacy and safety of injectable PTH without the need for daily subcutaneous injections. The responses to the prospect of prescribing an oral PTH were overwhelmingly positive, driven by expected improvements in patient compliance, ease of administration, and without injection site discomfort. Physicians also considered reduced costs to patients and payers to be important features. Entera’s EB613 oral PTH is currently in Phase 2 clinical development for the treatment of osteoporosis, a multi-billion dollar global market. “We are very pleased with the data from this important global market survey which very clearly validates the value proposition of our lead drug candidate, EB613. Due to the high cost, inconvenience, and pain associated with injectable osteoanabolic products, which are currently the standard of care for treating moderate to...